Loading
KYAN Technologies
KYAN Technologies uses a small set of live-cell experiments and its own AI to rank more than 1,500 personalised drug combinations for a patient's cancer.
Overview
KYAN Technologies, based in Singapore with US operations, markets Optim.AI, a functional precision medicine platform that tests a patient's live cancer cells against drugs and uses its algorithm to evaluate and rank over 1,500 personalised combinations. Physician-ordered.
Connected
2Similar pages
- CompanyTravera
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyFirst Ascent Biomedical
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- Company2cureX
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyCure-First
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanySageMedic
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanySpeciCare
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyStoreMyTumor
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyCanCertain
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
kyantechnologies.com · 1
sijbrandijfoundation.org · 1
A source that has moved or gone is reported by the weekly link check. /audit/